Cambrex Bio Science Baltimore and Cambrex Bio Science Walkersville, subsidiaries of Cambrex Corp., completed the production and packaging of CuraGen Corp’s CR011-vcMMAE, an investigational drug product currently in a Phase I study examining its use for the treatment of metastatic melanoma. CR011-vcMMAE is an antibody-drug conjugate (ADC) consisting of CR011, a fully-human monoclonal antibody linked to a cell-killing drug payload. Cambrex Bio Science Baltimore, Inc. scaled-up the CuraG...